Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 8, No. 4-5, 2008
Issue release date: October 2008
Section title: Original Paper
Free Access
Pancreatology 2008;8:520–531

Multicenter Approach to Recurrent Acute and Chronic Pancreatitis in the United States: The North American Pancreatitis Study 2 (NAPS2)

Whitcomb D.C.a, b · Yadav D.a · Adam S.a · Hawes R.H.c · Brand R.E.d · Anderson M.A.e · Money M.E.f · Banks P.A.g · Bishop M.D.h · Baillie J.i · Sherman S.j · DiSario J.k · Burton F.R.l · Gardner T.B.m · Amann S.T.n · Gelrud A.o · Lo S.L.p · DeMeo M.T.q · Steinberg W.M.r · Kochman M.L.s · Etemad B.t · Forsmark C.E.u · Elinoff B.a · Greer J.B.a · O’Connell M.a · Lamb J.a · Barmada M.M.b
Departments of aMedicine and bHuman Genetics, University of Pittsburgh, Pittsburgh, Pa.; cDigestive Disease Center, Medical University of South Carolina, Charleston, S.C.; dDepartment of Medicine, Evanston Northwestern Healthcare, Evanston, Ill.; eUniversity of Michigan, Ann Arbor, Mich.; fWashington County Hospital, Hagerstown, Md.; gDivision of Gastroenterology, Brigham and Women’s Hospital, Boston, Mass.; hDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Fla.; iDepartment of Medicine, Duke University Medical Center, Durham, N.C.; jDepartment of Medicine, Indiana University Medical Center, Indianapolis, Ind.; kDepartment of Medicine, University of Utah Health Science Center, Salt Lake City, Utah; lDepartment of Internal Medicine, St. Louis University School of Medicine, St. Louis, Mo.; mDartmouth-Hitchcock Medical Center, Hanover, N.H.; nNorth Mississippi Medical Center, Tupelo, Miss.; oDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio; pDepartment of Medicine, Cedars-Sinai Medical Center, University of California, Los Angeles, Calif.; qDepartment of Medicine, Rush University Medical Center, Chicago, Ill.; rWashington Hospital Center, Washington, D.C.; sDepartment of Medicine, University of Pennsylvania, Philadelphia, Pa.; tDepartment of Gastroenterology and Hepatology, Ochsner Medical Center, New Orleans, La., and uDepartment of Medicine, University of Florida, Gainesville, Fla., USA
email Corresponding Author

David C. Whitcomb, MD, PhD

UPMC Presbyterian, M2 C-Wing

200 Lothrop Street, Pittsburgh, PA 15213 (USA)

Tel. +1 412 648 9604, Fax +1 412 383 7236

E-Mail whitcomb@pitt.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) are complex syndromes associated with numerous etiologies, clinical variables and complications. We developed the North American Pancreatitis Study 2 (NAPS2) to be sufficiently powered to understand the complex environmental, metabolic and genetic mechanisms underlying RAP and CP. Methods: Between August 2000 and September 2006, a consortium of 20 expert academic and private sites prospectively ascertained 1,000 human subjects with RAP or CP, plus 695 controls (spouse, family, friend or unrelated). Standardized questionnaires were completed by both the physicians and study subjects and blood was drawn for genomic DNA and biomarker studies. All data were double-entered into a database and systematically reviewed to minimize errors and include missing data. Results: A total of 1,000 subjects (460 RAP, 540 CP) and 695 controls who completed consent forms and questionnaires and donated blood samples comprised the final dataset. Data were organized according to diagnosis, supporting documentation, etiological classification, clinical signs and symptoms (including pain patterns and duration, and quality of life), past medical history, family history, environmental exposures (including alcohol and tobacco use), medication use and therapeutic interventions. Upon achieving the target enrollment, data were organized and classified to facilitate future analysis. The approaches, rationale and datasets are described, along with final demographic results. Conclusion: The NAPS2 consortium has successfully completed a prospective ascertainment of 1,000 subjects with RAP and CP from the USA. These data will be useful in elucidating the environmental, metabolic and genetic conditions, and to investigate the complex interactions that underlie RAP and CP.

© 2008 S. Karger AG, Basel and IAP

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 05, 2007
Accepted: February 21, 2008
Published online: September 03, 2008
Issue release date: October 2008

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 7

ISSN: 1424-3903 (Print)
eISSN: 1424-3911 (Online)

For additional information: http://www.karger.com/PAN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.